CHAMGAP
APPROVEDReviewed and approved by the Chamgap Editorial Team (2026-07-10). The draft was written by AI, all 4 cited sources were opened and checked for existence, and the verdict passed blind grading and adversarial audit. Methodology v0.6.
Verdict No. 176 · Search date 2026-07-10 · Methodology v0.6

Mistletoe,
does it really help with Immunity, blood pressure, and anticancer effects (adjunctive therapy)?

30-Second Summary
D
Evidence Grade D · 34 · Safety warning
Anticancer survival and blood-pressure claims have not been confirmed, and the quality-of-life signal also has major methodological controversy, so the grade is D.
What the
research shows
Mistletoe injections have many European studies in adjunctive cancer care, but anticancer efficacy such as survival or tumor response has not been confirmed in high-quality evidence. There are signals for improved quality of life, but there is substantial controversy over study quality, blinding, and the anthroposophic-treatment context, while claims for blood pressure and general immune supplements have very weak human evidence.
What the
ads claim
Advertisements mention 'immune activation,' 'cancer adjunct,' 'anticancer,' and 'blood pressure' together. The actual evidence is concentrated in the quality-of-life debate around injectable adjunctive cancer therapy and is far from claims about oral supplements or blood pressure.
*

Useful facts when choosing a product

  • Most cancer studies are in the context of standardized injections, not oral health foods.
  • Local injection reactions, fever, allergy, and rare anaphylaxis are reported.
  • Clinician confirmation is especially needed with immune checkpoint inhibitors, autoimmune disease, and hematologic cancers.
  • Blood-pressure claims lack evidence beyond traditional use and pharmacologic plausibility.
Gap Measurement · Verdict 176 · D 34
What advertising claims
What independent, higher-quality research supports
△ GAP
01

What the research actually shows

The Horneber 2008 Cochrane review assessed 21 studies and concluded that evidence for survival benefit was not convincing and that study-quality problems were substantial. The Freuding 2019 systematic review summarized that high-quality studies did not show survival or quality-of-life benefits. The Loef 2020 meta-analysis reported a positive quality-of-life signal, but the included studies had substantial risk of bias and heterogeneity. For blood-pressure lowering, it is difficult to verify modern large placebo-controlled RCTs.

02

Why this is classified as D (34)

Human studies are not entirely absent, but the core anticancer and blood-pressure claims have not been confirmed in high-quality studies, so the grade is D, 34 points.

Counterpoint. If the question is narrowed to possible quality-of-life support, a C discussion is possible, but combined advertising claims about anticancer effects, blood pressure, and immunity should be rated lower.

Rejudgment record. Draft — Human studies are not entirely absent, but the core anticancer and blood-pressure claims have not been confirmed in high-quality studies, so the grade is D, 34 points.

Cross-check — Codex and Claude

This verdict was drafted by Codex through literature review and source-existence checks, cross-checked through blind grading and adversarial audit, and settled by reapplying the methodology boundary rules. Cases with split grades were resolved through rejudgment.
03

Evidence Table

StudyDesignSampleFundingEndpointResultWeight
Horneber MA et al. 2008Cochrane systematic review21IndependentSurvival, quality of life, and symptomsSurvival benefit was not confirmed, and study-quality limitations were substantial.Core
Freuding M et al. 2019Systematic reviewAcademicSurvival, quality of life, and adverse effectsIn high-quality studies, survival and quality-of-life benefits were not confirmed.Core
Loef M & Walach H 2020Systematic review and meta-analysisUnknown/complementary-medicine researchersQuality of lifeA positive quality-of-life signal was reported, but risk of bias was substantial.Supporting
§

Receipt — 4 References

Every cited source was opened and checked against the live page on 2026-07-10.

Horneber MA, Bueschel G, Huber R, Linde K, Rostock M. Mistletoe therapy in oncology. Cochrane Database Syst Rev. 2008;(2):CD003297. DOI: 10.1002/14651858.CD003297.pub2.
checked
Freuding M, Keinki C, Micke O, Buentzel J, Huebner J. Mistletoe in oncological treatment: a systematic review. J Cancer Res Clin Oncol. 2019;145:695-707. DOI: 10.1007/s00432-018-02837-4.
checked
Loef M, Walach H. Quality of life in cancer patients treated with mistletoe: a systematic review and meta-analysis. BMC Complement Med Ther. 2020;20:227. DOI: 10.1186/s12906-020-03013-3.
checked
National Cancer Institute. Mistletoe Extracts (PDQ).
checked
Draft and rewrite: Codex (AI) · Verification: Codex blind grading and adversarial audit · Final adjudication: Claude
Reviewed and approved: Chamgap Editorial Team · Approval date: 2026-07-10 · Corrections: none

Cite this verdict

Mistletoe (Viscum album) × Immunity, Blood Pressure, and Anticancer Effects (Adjunctive Therapy) Evidence Grade D card
[Chamgap] Mistletoe (Viscum album) × Immunity, Blood Pressure, and Anticancer Effects (Adjunctive Therapy) — Evidence Grade D·34. 4 cited sources checked. Source: https://health-receipt.pages.dev/en/verdicts/immunity/mistletoe-immune-bloodpressure-cancer/ · CC BY 4.0

CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.

!

What this document does and does not do

Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.